Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list, along with a number of others like Merck's (MRK) diabetes drug Janumet. "The Biden-Harris ...

Novo Nordisk (NVO) reported better-than-expected ... Shares of the Danish drugmaker rose ~4% in European trading, while Eli Lilly (LLY), its main rival in the obesity market, added ~2% in the ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

TBL 2, MTL 0 10:28 Victor Hedman (8) - Gage Goncalves, Anthony Cirelli Tampa Bay’s captain extended the visitors’ lead on a 4-on-1 rush. Forward Gage Goncalves entered the zone on the right ...

Novo Nordisk A/S today announced 2024 earnings ... If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. On Wednesday, Novo Nordisk A/S NVO ...

MONTREAL – The Canadiens look for a season sweep of the Tampa Bay Lightning in their final game before the 4 Nations Face-Off break at the Bell Centre on Sunday. As part of Family Weekend in ...

Despite the company’s enthusiasm, questions remain about how Novo's latest numbers can move the needle in a competitive market. The company's stock price decline of 4% on Friday seems to ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...